Trial reportJournal of the Chinese Medical Association : JCMA2019
Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
Trial report in Journal of the Chinese Medical Association : JCMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings.Natural products and bioprospecting · 2026Review
- Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Literature Review.International journal of molecular sciences · 2026Review
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
- Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial.International journal of surgery (London, England) · 2025Article
- Phytochemical based on nanoparticles for neurodegenerative alzheimer disease management: Update review.Discover nano · 2025Review
- Recent Advances in Drug Development for Alzheimer's Disease: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Advancements in Cyclodextrin Complexes with Bioactive Secondary Metabolites and Their Pharmaceutical Applications.Pharmaceutics · 2025Review
- Review
- Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease.Heliyon · 2024Review
- Article
- Recent advancements in the role of phytochemicals and medicinal plants in prophylaxis and management of Alzheimer's disease.Iranian journal of basic medical sciences · 2024Review
- The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease.Biomolecules · 2023Review
- Review
- Huperzine-A Improved Animal Behavior in Cuprizone-Induced Mouse Model by Alleviating Demyelination and Neuroinflammation.International journal of molecular sciences · 2022Article
- Pomegranate (Foods (Basel, Switzerland) · 2022Review
- A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.Neurochemical research · 2022Review
- Personalized Management and Treatment of Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- Neurotransmitters and molecular chaperones interactions in cerebral malaria: Is there a missing link?Frontiers in molecular biosciences · 2022Review
- Research progress in traditional Chinese medicine in the treatment of Alzheimer's disease and related dementias.Frontiers in pharmacology · 2022Review
- Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's Disease (AD) is associated with cognitive decline due to various pathological mechanisms. There are several acetylcholinesterase inhibitor compounds which can improve cognition, but Huperzine-A is a natural sesquiterpene alkaloid extracted from Chinese herb (Huperzia Serrata) which has rapid action.
methodsDouble blind study was conducted. Participants included 50 patients with AD and 50 healthy individuals. Patients were recruited from Civil and BV hospital Bahawalpur and Nishter hospital Multan, Pakistan during May 2017 until February 2018 who were stable on Huperzine-A medication. Patients were tested twice. First, at the time of diagnosis to determine baseline scores. Second, post eight weeks of Huperzine-A treatment. Healthy individuals had single testing session. Participants completed Addenbrooke's Cognitive Examination and Trail Making Test.
resultsPatients with AD showed cognitive and task switching deficits in contrast with healthy individuals. There was significant improvement in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance.
conclusionHuperzine-A is effective in reducing cognitive and task switching deficits in patients with AD.
Indexed as
Identifiers
30839402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.